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1. Introduction {#sec005}
===============

Autosomal recessive cerebellar ataxias (ARCAs) are clinically and genetically heterogonous group of disorders \[[@pone.0236808.ref001]\]. Of these ARCAs, ataxia with oculomotor apraxia type 1 (AOA1) is a disease characterised by early-onset cerebellar ataxia, oculomotor apraxia and severe sensorimotor peripheral axonal polyneuropathy \[[@pone.0236808.ref002]\]. The genetic cause of AOA1 is a mutation in the *APTX* gene on chromosome 9p13, which consists of seven exons and encoding for aprataxin (APTX) nuclear protein \[[@pone.0236808.ref003]\]. Aprataxin is a member of the histidine triad superfamily, which consists of three major domains: forkhead-associated, histidine, and zinc finger domains \[[@pone.0236808.ref004]\]. Aprataxin is considered a component of DNA end-processing, which is involved in the removal of adenosine monophosphate (AMP) from the 5'-termini of DNA breaks \[[@pone.0236808.ref005], [@pone.0236808.ref006]\]. Following the abortive attempts of DNA ligase to join the complementary strands during DNA replication, APTX helps creating a gap for single-stranded DNA break (SSB) repair. This suggests a potential role of APTX as a "proofreader" during DNA replication. Aprataxin protein is highly expressed in the cerebellum, basal ganglia, cerebral cortex, spinal cord and other nervous system tissues \[[@pone.0236808.ref002], [@pone.0236808.ref003]\].

The clinical manifestations among patients with AOA1 are variable regardless of mutation types. The majority of patients present with childhood onset progressive cerebellar ataxia (mean age of onset: 4.3 years; range: 2--10 years), followed by oculomotor apraxia with dis-coordinated eye movement, generalized areflexia and severe peripheral axonal sensorimotor polyneuropathy. Other symptoms including chorea, dystonia, limb weakness, hypoalbuminaemia and hypercholesterolaemiavary among patients. Cognitive impairment has been observed in different degrees among patients although intellect remains normal in some individuals \[[@pone.0236808.ref007], [@pone.0236808.ref008]\].

More than 40 different *APTX* mutations have been identified so far, including nonsense, missense, splice site, frameshift mutations, as well as a complete deletion of the *APTX* gene \[[@pone.0236808.ref002], [@pone.0236808.ref003], [@pone.0236808.ref008]--[@pone.0236808.ref012]\]. The most common form of ARCAs in Japan and Portugal is AOA1, with the c.689_690insT (p.Glu232fs) mutation being the most frequent one observed in Japan, while the c.837G\>A (p.Trp279X) was the most common mutation among the Portuguese patients \[[@pone.0236808.ref009], [@pone.0236808.ref013]\].

The diagnosis ARCAs is based on the history and the clinical examination, family history, genetic analysis and Sanger sequencing. Clinical examination, including sensorimotor and gait assessment, is required for accurate diagnosis of ARCAs subtypes and magnetic resonance imaging (MRI) is frequently used in assessing the degree of cerebellar atrophy. Currently, no treatment is available for ARCAs in general, and for AOA1 in particular.

The correlation between *APTX* genotype and phenotype has not previously been investigated in Middle Eastern patients, despite the high prevalence of consanguineous marriages in the region. In this study, we recruited two unrelated consanguineous Jordanian families, with affected individuals presenting with undiagnosed movement disorders. Thus, the aim of this study was to identify the possible genetic variants underlying cerebellar ataxia in these two families. In addition, we investigated the phenotypes of the *APTX* mutation identified by whole exome sequencing (WES) and the sensitivity to oxidative DNA damaging agents.

2. Materials and methods {#sec006}
========================

2.1. Ethics and family recruitment {#sec007}
----------------------------------

This study was conducted after receiving ethical approval from the Institutional Review Board (IRB/05/2017), at the Cell Therapy Center/the University of Jordan. Two unrelated consanguineous extended families, family A (n = 18) and family B (n = 4, all were siblings), were recruited into this study ([Fig 1](#pone.0236808.g001){ref-type="fig"}). The clinical manifestations varied among patients, but were identical in siblings. Written informed consents were obtained from all participants or their parents for inclusion in the study.

![Identification of disease-causing mutation and segregation analysis.\
**A)** Pedigrees of two unrelated families with AOA1 disease, carrying *APTX* nonsense truncating mutation (c.837G\>A; p.W279\*). **B)** The location of p.W279\* in the *APTX* gene occurs in the histidine triad (HIT) domain of the aprataxin protein. **C)** Sanger sequencing of the identified truncating mutation on exon 6 of the *APTX* gene, which occurs as homozygous mutant p.W279\* *APTX* gene mutation. The other sequences represent heterozygous mutant (A/G) or wild-type (A/A).](pone.0236808.g001){#pone.0236808.g001}

2.2. Clinical evaluation and sample collection {#sec008}
----------------------------------------------

Clinical evaluation involved detailed history, neurological examination, full blood count (FBC) and serum chemistry nerve conduction studies (NCS) and Magnetic Resonance Imaging (MRI) ([Fig 1A](#pone.0236808.g001){ref-type="fig"}; [Table 1](#pone.0236808.t001){ref-type="table"}). All patients were previously diagnosed with cerebellar atrophy based on the Magnetic Resonance Imaging (MRI) and Nerve Conduction Studies (NCS) results. Brain MRI and NCS were repeated in this study for the probands and some of the affected subjects. Peripheral blood samples for DNA/RNA extraction were collected from 22 study participants, 30 unaffected family members, and ten age and gender matched healthy controls. Full blood count (FBC), alpha-fetoprotein (AFP), albumin, creatine kinase and cholesterol levels were also measured using the same approach. Additionally, skin biopsies for fibroblasts culture were obtained from 6 AOA1 patients and 6 age and gender matched healthy controls.

10.1371/journal.pone.0236808.t001

###### Summary of the major clinical signs for the 22 AOA1 patients in the study.

![](pone.0236808.t001){#pone.0236808.t001g}

  Characteristics                                                 No. of cases/total study subjects   Percentage %
  --------------------------------------------------------------- ----------------------------------- --------------
  Number of families                                              2                                   \-
  Consanguinity                                                   2/2                                 \-
  Age of onset                                                    3--7 years                          \-
  **Clinical Features**                                                                               
  Peripheral sensory loss                                         22/22                               100.0
  Chorea                                                          22/22                               100.0
  Dysarthria                                                      22/22                               100.0
  Distal limb muscle wasting and weakness                         22/22                               100.0
  Oculomotor apraxia                                              17/22                               77.3
  History of cognitive impairment                                 22/22                               100.0
  **Biochemical finding**                                                                             
  Hypoalbuminaemia                                                10/22                               45.5
  Hypercholesterolaemia                                           16/22                               72.7
  Increased creatine kinase                                       6/22                                27.3
  Increased alpha-fetoprotein                                     8/22                                36.4
  **Neurological investigations**                                                                     
  **Nerve conduction study (NCS)** Peripheral axonal neuropathy   22/22                               100.0
  **Magnetic resonance imaging (MRI)** Cerebellar atrophy         22/22                               100.0

2.3. DNA extraction {#sec009}
-------------------

Peripheral blood samples for molecular genetic testing were collected from affected members of family A (n = 18) and family B (n = 4) and available parents and unaffected siblings from both families (n = 30). Genomic DNA extraction was carried out using QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer's instructions. The quantity and quality of the extracted DNA were assessed using NanoDrop 2000 spectrophotometer (ThermoFisher Scientific, USA). DNA was prepared for all patients identified in the pedigree ([Fig 1](#pone.0236808.g001){ref-type="fig"}).

2.4. Whole exome sequencing and data analysis {#sec010}
---------------------------------------------

Whole exome sequencing was performed for two probands from family A (V: 20, VI: 10) and one proband from family B (IV: 7) by Macrogen service (South Korea). Briefly, exome captures were completed using SureSelect Target Enrichment System (Agilent, Human All Exon Kits v6) (Santa Clara, Californian, U.S.A.) according to the manufacturer's protocol. The libraries were sequenced with Illumina NovaSeq6000 system (Illumina Inc., San Diego, CA). Sequence reads in FASTQ format were aligned to the human reference genome (GRCh37), using the Burrows-Wheeler Aligner (BWA) (<http://bio-bwa.sourceforge.net/>). Duplicates were removed with Picard ([http://picard.Sourceforget.net](http://picard.sourceforget.net/)). WES data were analysed using Genomic Analysis Tool Kit (GATK) (<http://www.broadinstitute.org/gatk/>) and SnpEff (<http://snpeff.sourceforge.net/SnpEff.html>). The resulting Variant Call Format (VCF) files were then analyzed using Illumina basespace variant interpreter tool (<https://variantinterpreter.informatics.illumina.com/>). Variants with read depth less than 10 were excluded. To determine rarity of variants, minor allele frequencies from three publicly available databases were used (1000 Genomes, ExAC, and EVS). Variants occurring with a frequency of ≥1% were filtered out. Variant filtering was done under the hypothesis of autosomal recessive inheritance. Then, the variants were filtered using a virtual gene panel of more than 100 neuropathy-related genes. Candidate variants identified through filtering were further analysed for their in silico predicted effect on protein function. The filtered variants were queried in the ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) and Human Gene Mutation Database (HGMD).

2.5. DNA amplification and Sanger sequencing {#sec011}
--------------------------------------------

To identify the presence or absence of the mutation in the *APTX*, the region around the mutation was amplified by PCR and sequenced using the same specific primers through Sanger method, to confirm the segregation of the pathogenic variant detected in patients' families.

Forty-three members from family A (18 affected and 25 healthy) and 9 members from family B (4 affected and 5 healthy) were tested. PCR amplification was carried out using Platinum^™^ PCR SuperMix (Invitrogen, USA) and 300 nM primer pair flanking the variant sites (ARTX Fwd: `5’-CAGAGGCTTTTCCCATTTTG-’3`, ARTX Rev: `5’-AGCTTTCTAGGTCCCCCAAG-’3`), 50 ng/μl DNA, and water were mixed to reach a total of 25 μl as the final volume. An initial denaturation step at 94° for 3 minutes was followed by 35 cycles of 94° for 30 seconds, 58° for 30 seconds for annealing, 72° for 30 seconds for elongation, and final extension at 72° for 7 minutes. The PCR products were evaluated using a 2% agarose gel electrophoresis with expected amplicon size of 586 bp. PCR products were then purified by GeneJET PCR purification kit (ThermoFisher, USA) and labelled with BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, USA). The aforementioned PCR primers (ARTX Fwd and ARTX Rev) were used as sequencing primers. Labelled PCR products were purified using NucleoSEQ^®^ columns (Macherey-Nagel, Düren, Germany) and then analyzed by ABI 3500 genetic analyzer (AppliedBiosystem). Sequence data were analyzed with SeqA software (Applied Biosystems, USA) and Chromas Pro software (Technolysium LTD, South Brisbane, Australia).

2.6. Analysis of mRNA by quantitative reverse-transcription PCR (qRT-PCR) {#sec012}
-------------------------------------------------------------------------

Extraction of RNA from fibroblasts and peripheral blood samples was done on samples collected from affected individuals and healthy controls subjects with no history of neurodegenerative diseases using TRIzol reagent, and purified with RNeasy Mini kit according to the manufacturer's instructions (Qiagen, USA). First strand cDNA synthesis was performed using GoScript Reverse Transcription System (Qiagen, USA), with 1 μg of RNA from each sample and using both oligo (dT)^15^ and random primers. Each qRT-PCR reaction was composed of GoTaq^®^ qPCR Master Mix (Promega, USA), 300 nM of each forward (`5’-CCGACTTCTGGAGAGTGATGA-3’`) and reverse (`5’-ACGCCCAATCACAACTGCTT-3’`) primers specific for *APTX* gene and 20 ng of cDNA template. Mixtures were run on CFX-96 (BioRad) according to the following protocol: 95°C for 3 minutes, 95°C for 10 seconds and 64°C for 1 minute (40 cycles). Samples were performed in technical triplicates, and average Ct-values were used for calculations. Data are represented using the ΔΔCt method. Fold changes were calculated as the average fold change based on GAPDH gene forward primer (`5’-CCTGTTCGACAGTCAGCC-3’`) and reverse primer (`5’-CGACCAAATCCGTTGACTCC-3’`), and ß-actin gene forward primer (`5’-GGACTTCGAGCAAGAGATGG-3’`) and reverse primer (`5’-AGCACTGTGTTGGCGTACAG-3’`).

2.7. Western blot {#sec013}
-----------------

Western blotting was carried out on whole cell lysates extracted using RIPA buffer (Thermo, USA) on ice. Whole protein was extracted from 4 patients' and 4 healthy controls' fibroblasts and quantified using BCA quantification kit (Abcam, UK). The details were as follows: 20 μg of each sample were denatured in Laemmli buffer for 5 minutes at 95°C. Protein separation was achieved using SDS polyacrylamide gel electrophoresis and transferred onto PVDF membrane using Trans-Blot^®^ SD semi dry transfer system (BioRad, USA). Membranes were blocked with 5% skimmed milk in TBST buffer for 1 hour and then incubated with primary antibodies, diluted in 1% blocking buffer at 4°C overnight. After that, they were washed and incubated with HRP-conjugated secondary antibodies for 1 hour at room temperature. Washed immunoblots were then incubated with TMB substrate (Promega, USA) for 2 minutes. Image acquisition was performed using ChemiDoc imaging system (BioRad, USA). Antibodies used: rabbit anti-aprataxin (1:500; Abcam, ab192598) and mouse anti-β-actin (1:500; Abcam, ab8227), anti-rabbit IgG H&L (1:1000, Abcam, ab6721), and anti-mouse IgG H&L (1:1000, Abcam, 6728).

2.8. Cell culture and genotoxicity analysis {#sec014}
-------------------------------------------

Fibroblasts were isolated from skin biopsies of 6 healthy controls and 6 patients carrying the identified *APTX* mutation. Cells were cultured in Advanced DMEM/F-12 (Dulbecco\'s Modified Eagle Medium/Ham\'s F-12) (ADMEM, Gibco) containing 10% fetal bovine serum (FBS) (Gibco), 2mM L-glutamine (Life Technologies), 100 U/ml penicillin and streptomycin (Gibco) and maintained in a humidified incubator under 37°C and 5% CO~2~. Cells were cultured in 96-well plates at a density of 5000 cells/well. The following day, cells were treated in triplicates with increasing concentrations of mitomycin-C (MMC), methyl-methane sulfonate (MMS) and etoposide for 1 hour, and H~2~O~2~ for 30 minutes, under 37°C and 5% CO~2~. Cells in normal culture media with no treatment served as a control. To assess the effect of these different genotoxic agents on cell survival, we performed MTT assay \[3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide\] (Promega, USA) after 48 hours of treatment and the percentage of viable cells was calculated accordingly.

2.9. Statistical analysis {#sec015}
-------------------------

The data was analysed using GraphPad Prism software version 6.0. The results were expressed as means ± standard deviation (SD). Statistical significance was analysed by two-way analysis of variance (ANOVA), followed by Bonferroni test for multiple comparisons. A value of p\* \< 0.01 was considered as significant.

3. Results {#sec016}
==========

3.1. Clinical presentation of AOA1 patients {#sec017}
-------------------------------------------

All patients had typical symptoms of cerebellar ataxia with disease onset at age of 3--7 years, clinical evidence of cerebellar ataxia, severe sensorimotor peripheral neuropathy with distal muscle wasting and weakness affecting predominantly the lower limbs and chorea ([Table 1](#pone.0236808.t001){ref-type="table"}). All patients were previously diagnosed with Nerve Conduction Study (NCS) and Magnetic resonance imaging (MRI) and they all showed reduced nerve conduction velocities and very small / absent sensory and motor action potentials ([S1 Fig](#pone.0236808.s001){ref-type="supplementary-material"}). Oculomotor apraxia was observed in most cases of family A (72.2%, n = 13/18) and in all of the four cases of family B (n = 4/4). History of mild to moderate cognitive impairment was noted in 72.7% of all patients. Biochemical analysis showed that serum cholesterol levels were elevated in 16 patients (72.7%), albumin levels were decreased in 10 patients (45.5%), AFP levels were slightly elevated in eight patients (36.4%) and creatine kinase levels were elevated in 6 patients (27.3%, [Table 1](#pone.0236808.t001){ref-type="table"}). Molecular testing of parents and siblings was carried out to confirm variant segregation ([Fig 1A--1C](#pone.0236808.g001){ref-type="fig"}). All patients had severe axonal sensorimotor peripheral neuropathy with reduced nerve conduction velocities and very small / absent sensory and motor action potentials and cerebellar atrophy on brain MRI.

3.2. Whole exome sequencing and segregation analysis {#sec018}
----------------------------------------------------

Genomic DNA was extracted from patients' peripheral blood samples and WES was performed for three probands; two from two different generations of family A (V:20, VI:10) and one from family B (IV:7) ([Fig 1A](#pone.0236808.g001){ref-type="fig"}). WES has generated 150 bp average sequence reads length, with 71% on-target reads and 97% target reads coverage at 30X. Based on our filtering criteria, the exome-sequencing analysis of both families resulted in the identification of a homozygous recurrent truncating mutation in *APTX* c.837G\>A located at Chr9:32,974,493 and predicted to introduce a stop codon and premature truncation in aprataxin protein (p.W279\*) ([Fig 1B and 1C](#pone.0236808.g001){ref-type="fig"}). This variant is a nonsense mutation located in exon 6 in the histidine triad (HIT) domain region of the protein, which is predicted to cause complete loss of the aprataxin zinc-finger domain ([Fig 1B](#pone.0236808.g001){ref-type="fig"}). The presence of the mutation was also confirmed in all other affected members by Sanger sequencing. *APTX* segregation analysis was performed to identify the mutation among parents and siblings of the affected members. Sanger sequencing confirmed the segregation of *APTX* p.W279\* variant and determined that the variant is fully segregated with disease in affected family members, while the healthy subjects were either heterozygous carriers or wild type. All parents tested were heterozygous carriers ([Fig 1A and 1C](#pone.0236808.g001){ref-type="fig"}).

3.3. *APTX* mRNA and protein analysis {#sec019}
-------------------------------------

To assess the effect of the detected mutation on gene expression and protein level we used qRT-PCR and western blot. Measurements of mRNA levels using qRT-PCR revealed no significant difference in the level of *APTX* expression between patients and controls in peripheral blood samples when normalized to GAPDH and ß-actin gene levels ([Fig 2A](#pone.0236808.g002){ref-type="fig"}). A significant difference in the level of *APTX* was observed in fibroblast samples (\*\*P \< 0.001) ([Fig 2B](#pone.0236808.g002){ref-type="fig"}). However western blot analysis using anti-aprataxin antibody directed towards the N-terminal region of the protein did not show any detectable levels of the protein. This might suggest that non-sense mediated decay (NMD) could be involved in the clearance of the transcripts with the premature stop codon ([Fig 2C](#pone.0236808.g002){ref-type="fig"}).

![*APTX* mRNA and protein analysis.\
Gene expression level of *APTX* mRNA. Quantitative RT-PCR of *APTX* mRNA in peripheral blood mononuclear cells (A), and in fibroblasts (B), normalized to GAPDH and ß-actin gene levels, respectively. (C) Western blot analysis of WT and mutated APTX proteins. APTX levels were normalized against β-actin protein. Patients carrying *APTX* mutations showed no detectable level of the mutated *APTX*. While healthy controls showed APTX protein with an expected size \~40 kDa. Results represent the means ± standard deviation (SD) calculated from three independent experiments (ns: non-significant, testing was done using two-way ANOVA followed by Bonferroni test).](pone.0236808.g002){#pone.0236808.g002}

3.4. *APTX* mutation and DNA SSB repair {#sec020}
---------------------------------------

Since aprataxin protein is involved in SSB system, mutations in this protein may render the *APTX* mutant cells more sensitive to genotoxic agents. In order to investigate sensitivity of patients' cells to genotoxicity, fibroblast cells were exposed to increasing doses of the following DNA-damaging agents: H~2~O~2~, MMC, MMS and etoposide. The number of viable cells was estimated after 48 hours of treatment in drug-free medium. APTX-defective cells were more sensitive to high concentrations of H~2~O~2~ (0.5 mM and 1.0 mM; p\<0.010 for both concentrations; ANOVA), MMC (20 μM and 30 μM, p\<0.010 and p\<0.001, respectively; ANOVA) and etoposide (25 μM and 50 μM, p\<0.001 for both concentrations; ANOVA ([Fig 3A--3D](#pone.0236808.g003){ref-type="fig"}). No significant changes were observed on any of the MMS concentrations used. Collectively, these results indicate a clear difference between patients and controls, displayed as reduced rates of SSB repair after treating cells with DNA damaging agents.

![Sensitivity assay of AOA1 fibroblasts to genotoxins.\
**(A-D)** Percentage of fibroblast cell survival after 48 hours of exposure to increasing concentrations of the following genotoxic agents: H~2~O~2~, MMC, MMS and etoposide at 37°C, respectively. Results were normalized to untreated controls. A statistically significant difference was observed after treatment of patients' cells with H~2~O~2~, MMC and etoposide. Results represent the means ± SD calculated from three to five independent experiments. (\*P \< 0.01; \*\*P \< 0.001; ns: non-significant).](pone.0236808.g003){#pone.0236808.g003}

4. Discussion {#sec021}
=============

Aprataxin is a nuclear protein composed of three domains; a forkhead-associated (FHA) N-terminal domain, a histidine triad (HIT) domain in the center and a zinc-finger (ZNF) C-terminus domain \[[@pone.0236808.ref002], [@pone.0236808.ref003], [@pone.0236808.ref014]\]. Aprataxin is highly expressed within the cerebellum, basal ganglia, cerebral cortex, and spinal cord \[[@pone.0236808.ref002], [@pone.0236808.ref003]\]. It has been shown that APTX is involved in single-strand DNA repair \[[@pone.0236808.ref015], [@pone.0236808.ref016]\], and mitochondrial transcriptional regulation \[[@pone.0236808.ref017]\]. It has also been demonstrated that aprataxin resolves the abortive DNA ligation caused by reactive oxygen species and failure of this process results in the accumulation of unrepaired DNA and cellular dysfunction \[[@pone.0236808.ref005]\]. Studies have confirmed that *APTX* mutations are involved in the degeneration of Purkinjie and cerebellar granular cells which are the most critical pathophysiological features responsible for cerebellar atrophy and ataxia \[[@pone.0236808.ref018], [@pone.0236808.ref019]\].

The *APTX* mutations were first described in Japanese and Portuguese families \[[@pone.0236808.ref002], [@pone.0236808.ref003]\]. To date, several mutations in the *APTX* gene have been reported to cause AOA1 disease. The majority of the previously reported mutations are either frameshift, missense, nonsense, splice-site or deletion mutations \[[@pone.0236808.ref002], [@pone.0236808.ref003], [@pone.0236808.ref014]\]. The most common mutation described worldwide is the p.Pro206Leu mutation, while among the European patients is the G837A (p.W279\*) mutation \[[@pone.0236808.ref003], [@pone.0236808.ref008]\].

In this study, WES was used to assist in the diagnosis of an unidentified cerebellar ataxia in two unrelated families with a high rate of consanguinity. Currently, WES has emerged as a more straightforward and cost-effective approach to screen pathogenic variants rather than using other traditional molecular diagnostic techniques.

Based on our filtering criteria and the recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology \[[@pone.0236808.ref020]\], we identified a recurrent variant of AOA1 in Jordanian families. This *APTX* truncating mutation p.W279\* was found in 22 individuals of 2 unrelated families, family A (n = 18) and family B (n = 4). Early-onset slowly progressive cerebellar ataxia, was found to be the presenting symptom in the majority of our cases described in this study. Oculomotor apraxia was observed in most cases of family A and all four cases from family B. Additionally, all affected members had cerebellar atrophy, severe peripheral neuropathy, distal wasting and weakness of upper and lower limb muscles and chorea.

The identified p.W279\* *APTX* mutation in our study has been previously illustrated in the literature \[[@pone.0236808.ref003]\] (Tranchant et al. 2003; Habeck et al. 2004), however, this is the first report of *APTX* mutation in patients from Jordan. Our identified *APTX* nonsense mutation (p.W279\*) is located in exon 6 in the HIT domain region of the protein, which is predicted to cause complete loss of the aprataxin zinc-finger domain. Tumbale et.al analysed the effect of different missense and nonsense mutants located within the *APTX* gene on protein solubility, stability and activity and found that: 1) some missense mutations were expressed within the cells, with contrasting solubility depending on the location of the mutation within the protein, 2) two nonsense *APTX* variants (p.R247\* and p.W279\*) are not expressed in the cells hence they were insoluble and highly destabilized, leading to the loss of the entire Znf domain, 3) the rest of the mutations were expressed within the cells but they were completely insoluble. Thus, they concluded that these substitutions lead to the disruption of the HIT domain structure \[[@pone.0236808.ref021]\].

In previous studies, the same research group reported that *APTX* truncating mutations are associated with early-onset cerebellar ataxia \[[@pone.0236808.ref008], [@pone.0236808.ref009]\]. The (689insT) truncation mutation in the *APTX* gene revealed the most severe phenotype with a mean age of onset 4.6 years, compared to patients with missense mutations who have less severe phenotype and mean of age of 15.1 years \[[@pone.0236808.ref007]\].

APTX interferes with the cellular response to genotoxic stress by interacting with DNA repair proteins \[[@pone.0236808.ref022]\]. The function of the aprataxin protein is to correct the 5'-adenylated DNA resulting from abortive ligations that might occur at any step during DNA replication or oxidative stress repair \[[@pone.0236808.ref005], [@pone.0236808.ref023], [@pone.0236808.ref024]\]. Furthermore, APTX protein interacts and forms a complex with XRCC1 and poly-ADP ribose polymerase 1 (PARP-1), implicating this protein with the detection and repair of single-strand DNA breaks \[[@pone.0236808.ref023]\].

It has been demonstrated that fibroblasts from patients with AOA1 are more sensitive to oxidative damage than normal fibroblasts, and an increase in oxidative DNA damage was observed in the cerebellum of AOA1 patients \[[@pone.0236808.ref023]\]. To assess the consequences of the identified mutation in our patients' cells, we examined the liability of the patient's fibroblast cells to oxidative stress by exposing them to increasing doses of DNA-damaging agents such as H~2~O~2~, MMS, MMC and etoposide. Thus, APTX-defective cells were significantly more sensitive to high concentrations of H~2~O~2~, MMC and etoposide with no significant changes observed in any of the MMS concentrations used. This might indicate that mutation-carrying cells may have reduced SSBs repair capability following treatment with DNA damaging agents \[[@pone.0236808.ref023]\]. Such results support the fact that AOA1 pathophysiology is correlated with aprataxin-defective fibroblasts hypersensitivity to reactive oxygen species, which results in an increasing number of SSBs and eventual cell death \[[@pone.0236808.ref015]\].

Our results are in partial agreement with two similar studies. The first study by Gueven et al reported that cells from AOA1 patients displayed sensitivity to H~2~O~2~ and MMS although similar sensitivity was not reported towards MMC \[[@pone.0236808.ref022]\]. On the contrary, in the second study reported the lack of toxicity when lymphoblastoid cell line from *APTX* mutated patients treated with H~2~O~2~ compared to control cells \[[@pone.0236808.ref025]\]. These inconsistencies might be due to the fact that different studies utilize different cell types from patients either affected with the same mutation or different mutations. One other possibility is the level of aprataxin protein varied in patients with certain types of mutations, which might lead to a decreased amount of the protein compared with other types of mutations. Additionally, certain types of mutations might affect protein stability when compared with wild-type aprataxin protein in vitro \[[@pone.0236808.ref015]\]. The difference in protein stability and amount among these mutated aprataxin proteins might explain the molecular mechanism of phenotype variation.

Also, the number of samples and their mutational background might have played a major role in this variability. Some studies were conducted on one lymphoblast cell line with one single termination mutation, others utilized a group of lymphoblastoid cell lines with different mutational backgrounds including missense as well as termination mutations. Therefore, a more comprehensive study needs to be conducted utilizing a large number of AOA1 patients, grouping them according to their mutational background and utilizing different methods to measure cellular viability to ensure the generation of consistent results.

In summary, this study highlights the importance of genetic diagnosis for neurological diseases such as ataxias, in which the phenotypic characterization is inefficient in defining disease type. Due to the high rate of consanguinity in the Middle East, identifying the genetic variants would help in restricting the spread of hereditary diseases. In the future, prospective screening of the identified mutations would become available for carriers within the same family and it will facilitate the diagnosis of affected children. In Jordan several related families presented with severe clinical manifestations including progressive ataxia, oculomotor apraxia and severe axonal sensorimotor peripheral neuropathy with no clear diagnosis. Our genetic analysis revealed the *APTX* nonsense variant leading to the termination mutation p.W279\*, which resulted in the lack of aprataxin protein expression in patients' fibroblast cells and showed hypersensitivity to several genotoxic agents. There is no available treatment for AOA1 and the current treatment strategies are based on rehabilitation therapy of disabilities. Despite these results, extensive experiments need to be conducted to uncover the exact pathophysiology of such mutations by disease modelling in neuronal cells derived either from autopsies or by cellular reprogramming, which could provide the chance to discover novel therapeutics in the near future.

5. Conclusions {#sec022}
==============

The diagnosis of some movement disorders should rely on genetic testing and clinicians should consider this when reporting cases of inherited movement disorders. This study is the first reports of patients withAOA1 in Jordan with p.W279\* *APTX* mutation and a heterogenous phenotype. It expands the spectrum of pathogenic *APTX* mutations associated with AOA1 and emphasizes the need of for genetic testing in patients with inherited movement disorders in patients from the Middle East, to assess the spread of founder mutations among consanguineous families.

Supporting information {#sec023}
======================
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Click here for additional data file.
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Click here for additional data file.
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Dear Dr. Ababneh,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Although this is only a case report, this is the first case from Jordan of APTX mutations found.  There are some issues that need to be addressed:.

1.  Whole exome sequencing for identification of mutations in one gene seems excessive.  The rationale for this approach should be better described and included in the Discussion.

2.  Address reviewer 1\'s points regarding the inconsistencies in the patient descriptions from line 229 and Figure1.

3.   Include more information in the Discussion on the impact of the results from this study.

4\. Address reviewer 2\'s comments about treatment of the cell lines.

5.  Ensure that mutation nomenclature is accurate.  (See Reviewer 1\'s comments).

6.  Ensure that all gene names are italicized.

7.  Include a link to the exome data as all data needs to be available. 

8.  PLOS ONE now requires that submissions reporting blots or gels include original uncropped blot/gel image data as a supplement or in a public repository.   This needs to be added to supplementary material.

9.  As one of the authors is affiliated with Prevention Genetics this needs to be included in the conflicts of interest section. 

10.  Address other points raised by the reviewers.

Please submit your revised manuscript by Aug 06 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Amanda Ewart Toland, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>
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\"This work was supported by the deanship of scientific research, University of Jordan, grant (2018- 2017/2)\"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"The author(s) received no specific funding for this work.\"

3\. Thank you for stating the following in the Competing Interests section:

\"The authors have declared that no competing interests exist.\"

We note that one or more of the authors are employed by a commercial company: Prevention Genetics.

3.1 Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

3.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

4\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank).
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Ababneh et al described a case of AOA1. This is the first case of the Jordanian.

Minor comments

L119 FBC should be fully spelled out at first appearance.

L229 All patients had typical symptoms of cerebellar ataxia with disease onset at age of 3-7 years, clinical evidence of cerebellar ataxia, severe sensorimotor peripheral neuropathy with distal muscle wasting and weakness affecting predominantly the lower limbs and chorea (Fig 1A, Table 1) Fig 1A is the familial pedigree tree. The sentence described above does not match the Fig 1A.

L236 albumin levels were elevated in 10 patients (45.5%). In tables 1, the author described as hypoalbuminemia. Usually, in AOA1, serum albumin level is decreased.

L236 AFP levels were observed in eight patients 236(36.4%). Does AFP increase or decreased? In tables 1, the author described as increased AFP. Usually in AOA1, serum AFP level is normal.

L261 APTX p.GW2 79\* → APTX p. W279\*

Reviewer \#2: The authors described a reported mutation, pW279\* in Jordan patients with AOA1. Fibroblasts from 6 patients were used.

The paper is well written, but no novel finding is described, except for the first report from Jordan. In addition, there are several points to be addressed.

Major points:

1\. The result of MMC, MMS, and H2O2 treatment is not new, with some discrepancies between the present results and the reported ones. The authors described that the discrepancies were attributed to a different mutation. How such mutational differences affect the result is important.

2\. Interesting thing is therapy, since the described mutation p.W279\* is a common mutation in AOA1. Please describe that prevention of cell death from the genotoxins.

3\. If proteasome inhibitors, such as lactascystin, are used, the truncated protein p.W279\* would be detectable?

Minor points:

1\. The human gene name should be in italicized, ex APTX.

2\. Figure legends were not present.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Editor:

Comment 1. Whole exome sequencing for identification of mutations in one gene seems excessive. The rationale for this approach should be better described and included in the Discussion.

Response: Thank you. The rationale has been described in the discussion and highlighted in yellow. Line: 333

In this study, WES was used to assist in the diagnosis of an unidentified cerebellar ataxia in two unrelated families with high rate of consanguinity. Currently, WES has emerged as a more straightforward and cost-effective approach to screen pathogenic variants rather than using other traditional molecular diagnostic techniques.

Based on our filtering criteria and the recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (20), we identified a recurrent variant of AOA1 in Jordanian families. This APTX truncating mutation p.W279\* was found in 22 individuals of 2 unrelated families, family A (n=18) and family B (n=4). Early-onset slowly progressive cerebellar ataxia, was found to be the presenting symptom in the majority of our cases described in this study.

Comment 2. Address reviewer 1\'s points regarding the inconsistencies in the patient descriptions from line 229 and Figure1.

Response: we have modified the patient descriptions as requested. The reviewer's points have been addresses and tracked in the same position.

Comment 3. Include more information in the Discussion on the impact of the results from this study.

Response: Thank you for your suggestion. We have added some data to the discussion as requested. Please see Line: 404 highlighted in yellow.

Comment 4. Address reviewer 2\'s comments about treatment of the cell lines.

Response: thank you, the comments have been addressed as requested.

Comment 5. Ensure that mutation nomenclature is accurate. (See Reviewer 1\'s comments).

Response: we have checked the mutation nomenclature and made the required correction.

Comment 6. Ensure that all gene names are italicized.

Response: All gene names have been changed to italic format.

Comment 7. Include a link to the exome data as all data needs to be available.

Response: we have provided a link at the end of the manuscript; line: 441

Comment 8. PLOS ONE now requires that submissions reporting blots or gels include original uncropped blot/gel image data as a supplement or in a public repository. This needs to be added to supplementary material.

Response: All uncropped blots have been added as supplementary material in PowerPoint document.

Comment 9. As one of the authors is affiliated with Prevention Genetics this needs to be included in the conflicts of interest section.

Response: Please note that the author 'Belal Azab' was affiliated to the University of Jordan during the time of the study. He has recently moved to the Prevention Genetics and there is NO COFLICT of interest to declare. He removed the prevention Genetics affiliation and he only kept the academic affiliations.

Comment 10. Address other points raised by the reviewers.

Response: Done, please find our point-by-point response in below.

Comment 11: We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"The author(s) received no specific funding for this work.\"

Response: Please kindly note that we have removed the funding information from the Acknowledgements sections. Please update our funding statement as the following: This work was supported by the deanship of scientific research, University of Jordan, grant (2018-2017/2). The funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of research materials.

3\. Thank you for stating the following in the Competing Interests section:

\"The authors have declared that no competing interests exist.\"

We note that one or more of the authors are employed by a commercial company: Prevention Genetics.

3.1 Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Response: Please note that the author 'Belal Azab' was affiliated to the University of Jordan during the time of the study. He has recently moved to the Prevention Genetics and there is NO COFLICT of interest to declare. He removed the prevention Genetics affiliation and he only kept the academic affiliations.
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Dear Dr. Ababneh,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Amanda Ewart Toland, Ph.D.

Academic Editor
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Dear Dr. Ababneh:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Amanda Ewart Toland

Academic Editor
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